Jason Broderick | Authors


Atezolizumab Combined With Cabozantinib Shows Efficacy in High-Risk mCRPC

September 19, 2021

According to updated data from the phase 1b COSMIC-021 trial, treatment with cabozantinib and atezolizumab continued to demonstrate clinically meaningful activity in previously treated patients with locally advanced or metastatic castration-resistant prostate cancer, including those with high-risk clinical features.